Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ONCS @ Stockcharts
Solid movement upward..200MA /MFI..added to my position!
ZACKS:$4.00
http://finance.yahoo.com/news/oncs-results-newly-initiated-phase-140000517.html
SEC-Form 4
http://openinsider.com/search?q=oncs
Incestor 100
HZNP:
Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone) Delayed-Release Tablets in Reducing Joint Stiffness of RA Throughout the Day
Data Also Presented on VIMOVO(R) (Naproxen/Esomeprazole Magnesium) in Reducing Knee Osteoarthritis Pain During the 2014 ACR/ARHP Annual Meeting
http://finance.yahoo.com/news/horizon-pharma-plc-announces-presentation-210500565.html
http://finance.yahoo.com/news/horizon-pharma-plc-present-26th-130000187.html
Investor 100
ALIM @ Stockcharts
Solid 10% gainer today...follow the money!
http://www.alimerasciences.com/
HEB @ Stockcharts
Like the play and news...huge volume!
http://money.cnn.com/2014/10/01/investing/ebola-drug-stocks-pharmaceuticals-outbreak-tekmira/index.html?iid=HP_LN
HE:Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
http://www.theflyonthewall.com/permalinks/entry.php/HEBid2075406/HEB-Hemispherx-expands-research-on-potential-Ebola-treatments?utm_source=twitterfeed&utm_medium=twitter&utm_campaign=theflyonthewall.com
HEB @ Stockcharts
Solid bounce w/news!
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
http://finance.yahoo.com/news/hemispherx-biopharma-united-states-army-123000254.html
SNGX @ STOCKCHARTS
Been a sleeper but like the charts and news took a starter position.
Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program (Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma)
http://finance.yahoo.com/news/soligenix-expands-pipeline-acquisition-phase-110000652.html
NVLX @ Stockcharts
Chart tells me to grab a starter...like the news too!
http://finance.yahoo.com/news/nuvilex-submits-application-orphan-drug-130000183.html
HZNP @ Stockcharts
Been a great trading stock this year and again moving up..
Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets
http://finance.yahoo.com/news/horizon-pharma-announces-u-patent-113000830.html Good till 2027!
Investor 100
ONCS @ Stockcharts
Looking to take a starter position.
Merkel Cell Carcinoma and Lymphoma
http://www.lymphomainfo.net/articles/leukemia/merkel-cell-carcinoma-and-lymphoma
Cutaneous T-Cell Lymphoma
http://www.lymphomainfo.net/nhl/types/ctcl-mf.html
Metastatic Melanoma
http://www.medscape.org/viewarticle/567508
Surgeon general issues skin cancer warning
http://www.cnn.com/2014/07/29/health/surgeon-general-skin-cancer/index.html
HZNP : Nice movement upwards with an 8% gain!
OT:Surgeon general issues skin cancer warning
Each year, more than 63,000 cases of melanoma are diagnosed in the United States, and 9,000 people die from it. From 1973 to 2011, melanoma rates increased more than 200%, according to the Department of Health and Human Services. The National Cancer Institute reported that melanoma is the most common form of cancer in adults ages 25 to 29 and second most common for young adults aged 15 to 29.
http://www.cnn.com/2014/07/29/health/surgeon-general-skin-cancer/index.html?hpt=he_c2
Investor 100
HZNP @ Stockcharts
Buying a starter on this dip!
http://www.thestreet.com/story/12823392/1/why-horizon-pharmaceuticals-hznp-is-plummeting-today.html?puc=yahoo&cm_ven=YAHOO
NEW YORK (TheStreet) -- Horizon Pharmaceuticals (HZNP_) plummeted Monday after the company said CVS Caremark (CVS_) and Express Scripts (ESRX_) would put Horizon's two best-selling drugs on their exclusion lists at the beginning of 2015.
The move to the exclusion list means patients would incur more of a cost for the drugs unless they switch to cheaper alternatives. CVS and Express Scripts are the largest and second-largest pharmacy benefit managers in the U.S.
The two drugs are Duexis, which treats arthritis pains for those with stomach issues, and Vimovo, which treats osteoporosis and rheumatoid arthritis. Horizon acquired the U.S. rights to Vimovo from AstraZeneca (AZN_) in November.
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
New Report Compares Achievable Concentrations of Various Candidate Treatments in Humans; CDC Issues New Guidelines for Protections
http://finance.yahoo.com/news/hemispherx-achieves-high-ranking-sensitivity-123000638.html
Investor 100
Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26
Looking to take a starter position!
http://finance.yahoo.com/news/hemispherx-biopharma-present-during-2014-123000417.html
Investor 100
HZNP @ Stockcharts
http://finance.yahoo.com/news/horizon-pharma-present-jmp-securities-113000652.html
http://seekingalpha.com/article/2271233-horizon-pharma-can-it-double-again
Stock has been a winner all year!
Investor 100
Happy Fathers Day @ Sheff Station!
Investor 100
OT:What do Americans spend fighting cancer?
http://www.cnbc.com/id/101718721
Half of all men and a third of all women in the U.S. will develop cancer in their lifetimes. The median age of diagnosis is 66 years old.
This year, an estimated 1.67 million new cases of cancer will be diagnosed in the U.S., with prostate, breast and lung cancers being the most common types.
The World Health Organization says more than 30 percent of cancer deaths could be prevented by modifying behaviors. Tobacco use is the single most important risk factor for cancer, accounting for about 22 percent of cancer deaths globally
Investor 100
OT:Pfizer ditches pursuit of AstraZeneca
http://money.cnn.com/2014/05/26/news/companies/pfizer-astrazeneca-deal/index.html?iid=HP_Highlight
Investor 100
OT:FAQ// S H E L F O F F E R I N G S
Often read that companies are doing shelf offers and with that here is a good article for that particular subject matter.
http://media.mofo.com/files/uploads/images/faqshelfofferings.pdf
Investor 100
GILD:Gilead jumps as sales of hepatitis C drug soars
http://www.usatoday.com/story/money/markets/2014/04/22/gilead-sciences-earnings/8032763/
Investor 100
OT: Happy Easter @ Sheff Station"
Investor 100
HZNP @ Stockcharts
A 2014 beastly run indeed...called it early got in at $8.50 2nd round..looking for $20!
Horizon Pharma to Host Corporate Update Meeting on March 27, 2014
http://finance.yahoo.com/news/horizon-pharma-host-corporate-meeting-113000527.html
OT:Cancer will be No. 1 killer in U.S.
http://www.cnn.com/2014/03/11/health/cancer-care-asco-report/index.html?hpt=hp_t3
Investor 100
HZNP @ Stockcharts
All indicators point upward..MFI..MACD..RSI..Follow the money given this is up 65% since I joined the board!
Buy Horizon Pharma On Upcoming Revenue Growth
http://seekingalpha.com/article/2069783-buy-horizon-pharma-on-upcoming-revenue-growth?source=yahoo
http://openinsider.com/search?q=hznp
HZNP @ Stockcharts
Been a solid winner in 2014...MFI..follow the money!
Why Horizon Pharma (HZNP) Is Up Today
http://www.thestreet.com/story/12283349/1/why-horizon-pharma-hznp-is-up-today.html?puc=yahoo&cm_ven=YAHOO
NEW YORK (TheStreet) -- Horizon Pharma (HZNP_) was rising 18.82% to $10.10 in afternoon trading on Wednesday after the pharmaceutical company announced its preliminary results for the fourth quarter and fiscal year 2013.
The company expects total net revenues to be between $31.9 million and $32.4 million for the fourth quarter and between $79.5 million and $80 million for the fiscal year. The company also provided an update on the status of its osteoarthritis drug VIMOVO and announced that all required FDA transfers, including the New Drug Application (NDA) and Investigational New Drug (IND), have been completed. Furthermore, Horizon-labeled inventory "has been manufactured, shipped and sold into the wholesale and pharmacy channel," according to the company's statement.